With the tariff threat headache over, time to focus on them again? 8 pharma stocks with upside potential of up to 39%

With a clear indication that no additional or special tariff will be imposed by the US on generic drugs, there is a sense of relief among Indian drug companies. The US healthcare system, too, must be relieved, given that India is the biggest supplier of generic drugs to the American market. Any increase in the cost of these medicines would have led to a disruption in the US healthcare system. Now that the tariff threat – which has been troubling Indian companies for the past year – is seemingly a thing of the past, will things get better on the street for Indian pharma companies?